Radiopharm Theranostics Limited

Description

Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. The firm aims to emerge as a recognised leader in some of the world’s largest markets in cancer.

Radiopharmaceuticals are safe radioactive drugs which can be employed as therapeutic or diagnostic tools.

A very small amount of safe radioactive medication is injected into the blood stream of patients. For diagnostics, low-energy radioisotopes are used, allowing physicians to observe and measure disease within the body, via imaging. While for therapeutics, high-energy radioisotopes are injected for the treatment of malignant tumours cancer.

As per the approved process, a radioisotope is attached to a targeting agent such as a small molecule or antibody.

Radiopharm Theranostics holds a strong pipeline of four licenced platform technologies – Nano-mAbs, Pivalate, AVβ6 Integrin and PSA-mAb. These technologies have diagnostic and therapeutic uses in both pre-clinical and clinical stages of development.

The firm is working in association with some of the world’s best universities and institutes, such as Memorial Sloan Kettering and Imperial College London.

Moreover, it is backed by a team of accomplished scientists of international renown in the radiopharmaceutical scientific community. Its Board comprises seasoned and experienced life science-focused directors with biotech and radiopharmaceutical experience.